Instead, immune checkpoint modulators that dampen immune activation—such as CTLA-4-Ig (abatacept)—have demonstrated efficacy in experimental autoimmune uveitis models by expanding Tregs and reducing pro-inflammatory Th17 cytokines, thus curbing inflammation. This evidence concerns the gene CTLA4 and autoimmune uveitis.